Amanote Research
Register
Sign In
Discover open access scientific publications
Search, annotate, share and cite publications
Publications by Tessa Brabander
Pitfalls in the Response Evaluation After Peptide Receptor Radionuclide Therapy With [ 177 Lu-Dota 0 ,Tyr 3 ]Octreotate
Endocrine-Related Cancer
Cancer Research
Endocrinology
Oncology
Metabolism
Diabetes
Peptide Receptor Radionuclide Therapy in Patients With Medullary Thyroid Carcinoma: Predictors and Pitfalls
BMC Cancer
Cancer Research
Oncology
Genetics
Related publications
Practıcal Aspects of 68Ga-Labelled Dota-Peptides for Peptide-Receptor Radionuclide Therapy
Journal of Engineering Technology and Applied Sciences
Nephrotoxicity After PRRT With 177Lu-Dota-Octreotate
European Journal of Nuclear Medicine and Molecular Imaging
Medicine
Nuclear Medicine
Radiology
Imaging
Predictors of Long-Term Outcome in Patients With Well-Differentiated Gastroenteropancreatic Neuroendocrine Tumors After Peptide Receptor Radionuclide Therapy With 177Lu-Octreotate
Journal of Nuclear Medicine
Medicine
Nuclear Medicine
Radiology
Imaging
Peptide Receptor Radionuclide Therapy
Best Practice and Research in Clinical Gastroenterology
Gastroenterology
Peptide Receptor Radionuclide Therapy
[ 177 Lu]-Psma-617 Radionuclide Therapy in Patients With Metastatic Castration-Resistant Prostate Cancer – Author's Reply
The Lancet Oncology
Oncology
New Developments in Peptide Receptor Radionuclide Therapy
Journal of Nuclear Medicine
Medicine
Nuclear Medicine
Radiology
Imaging
Reply: Peptide Receptor Radionuclide Therapy in the United States
Journal of Nuclear Medicine
Medicine
Nuclear Medicine
Radiology
Imaging
